our Premium Content: News alerts, weekly reports and conference planners

GENE:

FBXO9 (F-Box Protein 9)

News alerts, weekly reports and conference planners

17d

FBXO9 promotes anti-tumor immunity via degradation of PD-L1 in pancreatic cancer. (PubMed, Front Immunol)

Furthermore, FBXO9 expression correlates inversely with PD-L1 levels, with lower FBXO9 expression being associated with worse clinical outcome. These findings identify FBXO9 as a tumor suppressor via its facilitation of PD-L1 degradation, underscoring the potential of targeting FBXO9 in immunotherapeutic approaches for treating cancers, particularly in combination with anti-PD-L1 therapy.

17 days ago

Journal • PD(L)-1 Biomarker • IO biomarker

PD-L1 (Programmed death ligand 1) • FBXO9 (F-Box Protein 9)

6ms

FBXO9 mediated the ubiquitination and degradation of YAP in a GSK-3β-dependent manner. (PubMed, J Biol Chem)

These findings establish a previously unrecognized regulatory axis involving Akt, GSK-3β, FBXO9, and YAP that controls YAP protein turnover, providing a mechanistic basis for therapeutic strategies that combine Akt inhibitors with conventional chemotherapeutics. Our work advances the understanding of posttranslational YAP regulation and identifies several potential therapeutic targets for YAP-driven malignancies.

6 months ago

Journal

GSK3B (Glycogen Synthase Kinase 3 Beta) • FBXO9 (F-Box Protein 9)

11ms

Development and evaluation of an ovarian cancer prognostic model based on adaptive immune-related genes. (PubMed, Medicine (Baltimore))

Specifically, the low-risk group showed better prognosis, higher tumor mutational burden, greater response to immunotherapy, increased M1 macrophage and T follicular helper (Tfh) cell infiltration, and higher sensitivity to cisplatin and gemcitabine. Our findings highlight the significant association between AIRGs and the prognosis of OC. The prognostic model developed using AIRGs demonstrates strong predictive capabilities.

11 months ago

Journal • Tumor mutational burden • IO biomarker

TMB (Tumor Mutational Burden) • PIK3CD (Phosphatidylinositol-4 5-Bisphosphate 3-Kinase Catalytic Subunit Delta) • MALT1 (MALT1 Paracaspase) • CD79A (CD79a Molecule) • BTLA (B And T Lymphocyte Associated) • CD3G (CD3 Gamma Subunit Of T-Cell Receptor Complex) • CALM1 (Calmodulin 1) • FBXO9 (F-Box Protein 9)

cisplatin • gemcitabine

over1year

Construction of a five-gene-based prognostic model for relapsed/refractory acute lymphoblastic leukemia. (PubMed, Hematology)

We have developed a risk prediction model for pediatric R/R ALL utilizing the genes BAG2, EPHA4, FBXO9, SNX10, and WNK1. This model provides a scientific foundation for early identification of R/R ALL in children.

over 1 year ago

Journal • IO biomarker

PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • SOX2 • CD27 (CD27 Molecule) • CD3D (CD3d Molecule) • LCK (LCK Proto-Oncogene, Src Family Tyrosine Kinase) • WNK1 (WNK Lysine Deficient Protein Kinase 1) • CD3G (CD3 Gamma Subunit Of T-Cell Receptor Complex) • NANOG (Nanog Homeobox) • RASGRP1 (RAS Guanyl Releasing Protein 1) • VPREB1 (V-Set Pre-B Cell Surrogate Light Chain 1) • BLNK (B Cell Linker) • E2F1 (E2F transcription factor 1) • EPHA4 (EPH Receptor A4) • FBXO9 (F-Box Protein 9) • HOXB4 (Homeobox B4)

over1year

It also exhibited lower tumor mutation burden, mRNAsi, and EREG-mRNAsi and reduced sensitivity to other chemotherapy drugs, except dasatinib. These findings serve as a valuable indicator for personalized treatment strategies and clinical stratification in managing patients with EOC. Additionally, our study will serve as a foundation for future mechanistic research to explore the association between the ubiquitin-proteasome pathway and EOC.

over 1 year ago

Journal • Tumor mutational burden • IO biomarker

TMB (Tumor Mutational Burden) • CD4 (CD4 Molecule) • EREG (Epiregulin) • STAT1 (Signal Transducer And Activator Of Transcription 1) • VPS18 (VPS18 Core Subunit Of CORVET And HOPS Complexes) • AKAP12 (A-Kinase Anchoring Protein 12) • FBXO9 (F-Box Protein 9) • HSP90AB1 (Heat Shock Protein 90 Alpha Family Class B Member 1) • PPM1G (Protein Phosphatase, Mg2+/Mn2+ Dependent 1G)

TMB-L

dasatinib

almost2years

Ubiquitin ligase subunit FBXO9 inhibits V-ATPase assembly and impedes lung cancer metastasis. (PubMed, Exp Hematol Oncol)

These findings collectively elucidate the critical role of FBXO9 in regulating V-ATPase assembly and provide a molecular basis for FBXO9's function in inhibiting lung cancer metastasis. This highlights the potential therapeutic opportunities of FBXO9 supplementation.

almost 2 years ago

Journal

CUL1 (Cullin 1) • FBXO9 (F-Box Protein 9) • HSPA8 (Heat Shock Protein Family A (Hsp70) Member 8)

2years

Identification of a Prognostic Signature for Ovarian Cancer Based on Ubiquitin-Related Genes Suggesting a Potential Role for FBXO9. (PubMed, Biomolecules)

We identified and validated a signature of UbRGs that accurately predicts the prognosis, offers valuable guidance for optimizing chemotherapy and targeted therapies, and suggests a potential role for FBXO9 in OV.

2 years ago

Journal • Tumor mutational burden

TMB (Tumor Mutational Burden) • FBXO9 (F-Box Protein 9)

over3years

The cancer-testis antigen FBXO39 predicts poor prognosis and is associated with stemness and aggressiveness in glioma. (PubMed, Pathol Res Pract)

What's more, FBXO39 accelerates the invasion and migration abilities of glioma cells and promotes glioma stem cell growth and stemness. In summary, these results suggest that FBXO39 is expected to become a new biological target for judging the prognosis and treatment of glioma.

over 3 years ago

Journal

FBXW7 (F-Box And WD Repeat Domain Containing 7) • FBXO9 (F-Box Protein 9)

over3years

Comprehensive analysis and validation reveal potential MYCN regulatory biomarkers associated with neuroblastoma prognosis. (PubMed, J Biomol Struct Dyn)

In addition, FBXO9, RNF19B, and TRIM36 were preliminarily confirmed as potential target genes of MYCN. Overall, FBXO9, HECW2, MIB2, RNF19B, RNF213, TRIM36, and ZBTB16 are expected to become novel biomarkers for the treatment of high-risk NB patients.Communicated by Ramaswamy H. Sarma.

over 3 years ago

Journal

MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • ZBTB16 (Zinc Finger And BTB Domain Containing 16) • FBXO9 (F-Box Protein 9)

MYCN amplification